Santen Pharmaceutical Co., Ltd.

TSE:4536 Stock Report

Market Cap: JP¥662.0b

Santen Pharmaceutical Valuation

Is 4536 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4536 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4536 (¥1876.5) is trading below our estimate of fair value (¥2318.17)

Significantly Below Fair Value: 4536 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4536?

Other financial metrics that can be useful for relative valuation.

4536 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.9x
Enterprise Value/EBITDA8x
PEG Ratio2.2x

Price to Earnings Ratio vs Peers

How does 4536's PE Ratio compare to its peers?

The above table shows the PE ratio for 4536 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average12.6x
4528 Ono Pharmaceutical
8.4x-10.5%JP¥1.0t
4540 Tsumura
13x7.7%JP¥305.8b
4530 Hisamitsu Pharmaceutical
20.2x9.9%JP¥297.6b
4516 Nippon Shinyaku
8.6x-11.6%JP¥236.5b
4536 Santen Pharmaceutical
24.7x11.0%JP¥662.0b

Price-To-Earnings vs Peers: 4536 is expensive based on its Price-To-Earnings Ratio (24.7x) compared to the peer average (12.6x).

Price to Earnings Ratio vs Industry

How does 4536's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: 4536 is expensive based on its Price-To-Earnings Ratio (24.7x) compared to the JP Pharmaceuticals industry average (17.9x).

Price to Earnings Ratio vs Fair Ratio

What is 4536's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4536 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.7x
Fair PE Ratio24.4x

Price-To-Earnings vs Fair Ratio: 4536 is expensive based on its Price-To-Earnings Ratio (24.7x) compared to the estimated Fair Price-To-Earnings Ratio (24.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4536 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥1,876.50
JP¥1,983.00
+5.7%
15.2%JP¥2,500.00JP¥1,550.00n/a10
Aug ’25JP¥1,770.50
JP¥1,958.00
+10.6%
14.8%JP¥2,400.00JP¥1,600.00n/a10
Jul ’25JP¥1,656.50
JP¥1,866.67
+12.7%
18.6%JP¥2,400.00JP¥1,300.00n/a9
Jun ’25JP¥1,628.00
JP¥1,827.00
+12.2%
19.2%JP¥2,400.00JP¥1,300.00n/a10
May ’25JP¥1,523.00
JP¥1,767.00
+16.0%
15.8%JP¥2,200.00JP¥1,300.00n/a10
Apr ’25JP¥1,420.00
JP¥1,767.00
+24.4%
15.8%JP¥2,200.00JP¥1,300.00n/a10
Mar ’25JP¥1,493.00
JP¥1,738.89
+16.5%
16.2%JP¥2,200.00JP¥1,300.00n/a9
Feb ’25JP¥1,473.00
JP¥1,674.44
+13.7%
16.3%JP¥2,100.00JP¥1,300.00n/a9
Jan ’25JP¥1,405.00
JP¥1,635.56
+16.4%
16.0%JP¥2,000.00JP¥1,200.00n/a9
Dec ’24JP¥1,422.50
JP¥1,624.44
+14.2%
16.7%JP¥2,000.00JP¥1,200.00n/a9
Nov ’24JP¥1,323.50
JP¥1,585.56
+19.8%
14.5%JP¥1,900.00JP¥1,200.00n/a9
Oct ’24JP¥1,373.50
JP¥1,532.86
+11.6%
16.3%JP¥1,850.00JP¥1,200.00n/a7
Sep ’24JP¥1,357.50
JP¥1,403.33
+3.4%
20.1%JP¥1,850.00JP¥1,000.00n/a9
Aug ’24JP¥1,253.50
JP¥1,364.44
+8.9%
19.1%JP¥1,800.00JP¥1,000.00JP¥1,770.509
Jul ’24JP¥1,225.50
JP¥1,336.67
+9.1%
20.8%JP¥1,800.00JP¥1,000.00JP¥1,656.509
Jun ’24JP¥1,274.00
JP¥1,351.00
+6.0%
21.7%JP¥1,800.00JP¥980.00JP¥1,628.0010
May ’24JP¥1,163.00
JP¥1,296.00
+11.4%
20.5%JP¥1,800.00JP¥980.00JP¥1,523.0010
Apr ’24JP¥1,130.00
JP¥1,290.00
+14.2%
24.3%JP¥1,950.00JP¥870.00JP¥1,420.0010
Mar ’24JP¥1,022.00
JP¥1,295.00
+26.7%
24.4%JP¥1,950.00JP¥870.00JP¥1,493.0010
Feb ’24JP¥1,007.00
JP¥1,265.00
+25.6%
26.0%JP¥1,950.00JP¥870.00JP¥1,473.0010
Jan ’24JP¥1,074.00
JP¥1,266.00
+17.9%
25.9%JP¥1,950.00JP¥880.00JP¥1,405.0010
Dec ’23JP¥1,101.00
JP¥1,246.00
+13.2%
26.4%JP¥1,950.00JP¥880.00JP¥1,422.5010
Nov ’23JP¥1,001.00
JP¥1,241.00
+24.0%
25.2%JP¥1,950.00JP¥880.00JP¥1,323.5010
Oct ’23JP¥975.00
JP¥1,241.00
+27.3%
25.2%JP¥1,950.00JP¥880.00JP¥1,373.5010
Sep ’23JP¥985.00
JP¥1,287.00
+30.7%
27.8%JP¥1,950.00JP¥880.00JP¥1,357.5010
Aug ’23JP¥1,081.00
JP¥1,297.00
+20.0%
26.3%JP¥1,940.00JP¥880.00JP¥1,253.5010

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y